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Activated complement C3: A potentially novel predictor of progressive
IgA nephropathy. In the search for a serologic marker of disease activity,
we measured concentrations of activated C3 (actC3, that is, neoantigens
developing after C3 activation on breakdown products), C4-C3 complexes
and soluble C5b-9 (sC5b-9) in one or two plasma samples from adult
patients with IgA nephropathy (IgAN, N = 50) or Henoch-Schonlein
purpura (HSP, N = 4). As controls, 20 patients with non-immune renal
disease, but comparable age, degree of proteinuria, renal dysfunction and
prevalence of hypertension were studied. Compared to controls, actC3
levels were elevated in 30% of the patients with IgAN and one of the HSP
patients. C4-C3 complexes were elevated in only 8% of the IgAN patients,
and sC5b-9 levels were within the control range in all IgAN and HSP
patients. In IgAN patients with elevated actC3 levels, proteinuria and
hematuria were more pronounced than in those with normal levels.
Elevated plasma concentrations of actC3 at the first presentation corre-
lated with subsequent deterioration of renal function both in patients with
initially normal and already impaired renal function (r =
—0.56, N = 44,
P = 0.003). The five IgAN patients with elevated actC3 on both occasions
of obtaining plasma showed the most rapid loss of renal function. We
conclude that mainly alternative pathway complement activation can be
demonstrated in patients with IgAN and HSP. In IgAN patients the
presence of complement activation is associated with more severe renal
disease. Further studies are warranted to examine the clinical usefulness
of actC3 as a predictor of the subsequent course of IgAN.
IgA nephropathy (IgAN), presenting as isolated glomerular
disease (primary IgA nephropathy) or as a part of Henoch-
Schönlein purpura (HSP), is among the most common types of
glomerulonephritis worldwide [1—3]. About 20 to 30% of the
patients with IgAN will develop progressive renal failure within 10
to 20 years after the onset of disease [4—7]. Limited data suggest
that a similar percentage may also apply to HSP in adults [8, 9].
Epidemiologic studies have identified that some clinical parame-
ters, such as the degree of proteinuria, or the presence of
hypertension or impaired renal function, are associated with an
increased risk of progressive renal disease, but these parameters
are relatively non-specific and not particularly reliable for the
individual patient [4—7]. At present, no serologic tests are avail-
able that can be employed to assess disease activity in IgAN or to
predict renal outcome.
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The ability of IgA to cause renal injury via activation of the
complement system has long been controversial [10]. Recently,
convincing in vivo evidence has been presented that, in the rat,
dimeric and polymeric IgA can activate complement via the
alternative pathway to induce glomerular damage [11, 12]. In
patients with IgAN or HSP, complement activation has been
shown to occur both at the glomerular as well as systemic levels
and has been implicated in the pathogenesis of renal disease [1, 2,
13—15]. In the present study we investigated whether an assess-
ment of systemic complement activation correlates with clinical
indices of renal disease activity, and in particular, whether it has a
predictive value for the subsequent course of the disease. Such
data could not only strengthen the evidence for a pathogenetic
role of the complement system in IgAN, but could also lay the
basis for future therapeutical trials by tailoring treatment to high
risk patients.
In the current study we have employed some novel assays,
which allow a sensitive detection of complement activation. The
study was specifically designed to preclude any ex vivo comple-
ment activation after obtaining blood samples and to avoid the
assessment of low molecular weight complement components,
whose plasma concentration might be influenced by renal dysfunc-
tion. Consequently, the following complement components were
chosen: (1) activated C3 (actC3) [16], that is, neoantigens which
develop on C3 breakdown products following activation of either
pathway; (2) C4-C3 complexes [17], a marker of classical pathway
complement activation; and (3) soluble C5b-9 (sC5b-9) [18], that
is, the late membrane atttack complex which is formed following
activation of either pathway.
Methods
Patients
Plasma samples of three groups of patients were analyzed: (A)
50 patients with primary IgAN; (B) 4 patients with HSP; and (C)
20 patients with various non-immune renal diseases (Table 1).
Plasma samples obtained from 60 healthy persons served as
normal controls. In all patients of groups A and B the diagnosis of
IgAN had been established by renal biopsy, which exhibited
typical findings upon light microscopical, immunohistological and
electron microscopical examination (performed by U. Helmchen,
University of Hamburg, Germany). HSP was diagnosed in cases
with a biopsy proven IgAN and typical systemic symptoms.
Patients with liver disease, chronic inflammatory disease of the
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Table 1. Characteristics of the patients studied
Group
Non-
immune
renal
IgAN(N = 50)
HSP
(N = 4)
disease°
(N = 20)
Sex m:f 39:11 2:2 14:6
Age years 36 12
(18—69)
33 13
(18—50)
43 17
(18—74)
Follow-up' months 29 22 33 21 none
Percent of patients
(4—87)
82%
(3—49)
75% 80%
with hypertension
Serum creatinine 199 221 133 52 172 103
pinol/liter' (60-1582) (62-188) (70-450)
ProteinuriaC g/24 hr 3.5 3.5 3.4 2.3 2.4 3.2
Hematuria°"
(0.0—13.2)42 41 (1.5—7.3)57 44 (0.0—10.1)20 32
,nillion eythro./ (0—100) (2—93) (0—100)
24 hr
Data are absolute or relative frequencies or means so and (range)
Includes hypertensive renal damage, Alport's syndrome, polycystic
kidney disease, thin basement membrane disease and reflux nephropathy
h Clinical follow-up after obtaining the first plasma sample (available in
44/50 patients with IgAN and 4/4 patients with HSP)
C At the time of obtaining the first plasma sample
d Groups significantly different (P < 0.05 by Kruskal Wallis testing)
skin, gastrointestinal tract or respiratory tract, malignancies, or
other systemic diseases were excluded from the study. No patient
showed clinical symptoms of infections at the time of the exami-
nation.
Of the IgAN and HSP patients studied, one to two plasma
samples (total of 98 samples) were obtained. The time elapsed
between the two plasma samples ranged from 1 to 61 months. A
single sample was obtained from all patients with non-immune
renal disease. To avoid & vivo complement activation, 10 ml blood
was drawn into tubes containing 20 mivi EDTA and 100 jIM
benzamidine (both from Sigma, Deisenhofen, Germany), centri-
fuged within one hour after obtaining the sample, and the plasma
was then immediately aliquoted and stored at —70°C until the
assay. Storage durations of the plasma samples obtained the three
patient groups were not significantly different (range 12 to 96
months), but were below 12 months in the samples obtained from
normal controls.
Data obtained at each patient visit included measurements of
serum creatinine, creatinine clearance as well as a quantitative
determination of 24-hour urinary protein and erythrocyte excre-
tion using standard methodology. For the purposes of calculations
microhematuria of greater than 100 million erythrocytes per day
was set as 100. No patient showed macrohematuria at the time of
presentation. In 44 (88%) of the IgAN patients clinical follow-up
of at least six months including at least five determinations of
serum creatinine were available. These data served to calculate
the slope of 1/creatinine.
Antibodies and reagents for ELISAs
The following antibodies and reagents were used in the
ELISAs: peroxidase-conjugated monoclonal antibody M4d2
against human complement component C4 that recognizes C4,
C4b, and C4d [151; monoclonal antibody M4c3 against the y-chain
of C4, C4b and C4c [15]; monoclonal antibody 13/15 against a
neoepitope on human C3b, iC3b, C3dg [16]; monoclonal antibody
W13/15 against a human C9 neoantigen [18]; peroxidase-conju-
gated rabbit IgG anti-human C3d (Dakopatts, Hamburg, Ger-
many), biotinylated polyclonal goat antibody against human C6
[19]; peroxidase-coupled streptavidin (Amersham, Braunschweig,
Germany).
ELISA for the measurement of activated C3
This assay was performed as described elsewhere [161. Micro-
titer plates (Immunoplate Maxisorp; Nunc, Wiesbaden, Ger-
many) were coated overnight with 100 d of antibody 13/15 at 5
j.tg/ml in 0.05 M carbonate buffer pH 10.6. After washing in
phosphate buffered saline (PBS, pH 7.2) non-specific binding
capacity was blocked with 0.05 M carbonate buffer pH 10.6
containing 1% (wt/vol) gelatin. After washing with PBS/0.05%
Tween-20 100 p.l samples in duplicate 1:50 dilutions in PBS/0.05%
Tween-20/0.02 M EDTA were added for two hours at room
temperature. After washing with PBSiTween-20 100 jd of perox-
idase-conjugated rabbit anti-human C3d (Dakopatts) in PBS/
Tween-20 were added and incubated for another one hour at
room temperature. Finally, streptavidin-horseradish peroxidase-
conjugate was added for one hour at room temperature. Deter-
minations of actC3 were performed by colorimetric analysis of the
peroxidase-mediated hydrolysis of 2 mM 2,2'-azino-di-(3-ethyl
benzthiazolinesulfonate) (ABTS, Boehringer Mannheim, Ger-
many) in substrate buffer (100 m sodium acetate, 50 m sodium
phosphate, pH 4.2) containing 2.5 mrvi H202. Absorbance was
measured at 410 nm (reference wavelength 490 nm) using a
microplate photometer (ThermoMax; Molecular Devices, Menlo
Park, CA, USA). ActC3 concentrations in the samples were
calculated from calibration curves obtained by plotting the absor-
bance of purified protein C3b on a double log scale. C3b was
generated as described recently [16]. Since purified C3 fragments
C3b, iC3b and C3dg have been shown to give identical signals on
a weight basis the amount of activated C3 in samples was
expressed as g C3b/iC3b/C3dg per ml.
ELISA for the measurement of C4-c3 complexes
This assay was performed as described elsewhere with minor
modifications [171. Microtiter plates (Immunoplate Maxisorp;
Nunc) were coated overnight with 50 j.rl/well of antibody 13/15
against actC3 at 10 jig/mI in PBS. Blocking was performed with
PBS/1% bovine serum albumin (BSA) for one hour at room
temperature. After washing in PBS, pH 7.2 duplicate samples (50
1id), diluted 1:11 in PBS/0.02 M EDTA/1% BSA, were incubated
for two hours at 37°C. After washing in PBS/0.05% Tween-20
peroxidase-coupled antibody M4d2 against C4/C4b/C4d was
added and incubation continued for another two hours at 37°C.
Finally, wells were washed and 0.3 mrvt 3,3',5,5'-tetramethylben-
zidine dihydrochioride (TMB) (Fluka, Neu-Ulm, Germany) in
substrate buffer (0.1 M citric acid, 0.2 M disodium hydrogen
phosphate) containing 2.5 mrvi H202 was added. The reaction was
stopped after two to five minutes by adding an equal volume of
I M H2504. Absorbance was measured at 450 nm using a
microplate reader (ThermoMax; Molecular Devices). A standard
curve for the quantitation of C4-C3 complexes was obtained by
serially diluting normal human serum activated with 500 jig
heat-aggregated human IgG (HAG)/ml serum in PBS/0.02 M
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EDTAJI % BSA. The C4-C3 values were expressed as jxg HAG-
equivalent (Equ)/ml.
ELISA for the measurement of sC5b-9
The sC5b-9 ELISA was performed essentially as described {18j
with minor modifications. Microtiter plates (Immunoplate Maxi-
sorp; Nunc) were coated overnight with 100 jil of antibody
W13/15 against a C9 neoantigen at 5 tg/ml in 0.05 M carbonate
buffer pH 10.6. Non-specific binding was blocked by incubating
the plates with 0.05 M carbonate buffer pH 10.6 containing 1%
(wt/vol) gelatin and by incubating plasma samples with heat-
aggregated goat IgG (1 mg/i ml plasma) for 30 minutes. After
washing the plates with PBS/0.05% Tween-20 duplicate samples
(100 jd of 1:2 dilutions in PBS/0.05% Tween/0.02 M EDTA)
were added for two hours at room temperature. After washing
with PBS/Tween-20, biotinylated goat anti-human C6 in PBS!
Tween-20 (100 pl) was added and incubated for another one hour
at room temperature. After a final wash, streptavidin-horseradish
peroxidase-conjugate was added and incubated for one hour at
room temperature. Finally, TMB was added as has been described
for the C4-C3 ELISA. The sC5b-9 assay was calibrated using a
standard of human zymosan-activated serum with known sC5b-9
content (provided by Dr. Thomas Lint, Rush Presbyterian St.
Lukes Medical Center, Chicago, IL, USA).
Statistical analysis
All values are expressed as mean SD. Statistical significance
(defined as P < 0.05) was evaluated using either the Kruskal-
Wallis test or Mann-Whitney U-test for non-parametric popula-
tions. Correlation coefficients were calculated using the Spearman
rank test for non-parametric populations. Slopes of 1/creatinine
were calculated using linear regression analysis.
Results
Presence of alternative or classical pathway complement activation
in patients with IgAN and HSP
As shown in Table 1, the three groups of patients were
comparable in their age, frequency of hypertension, degree of
renal dysfunction and proteinuria. Kruskal-Wallis testing revealed
that of the parameters depicted in Table I only the degree of
hematuria was significantly different between the three groups.
A
IgAN HSP Non-IgAN
C
IgAN HSP Non-IgAN
400
300
200
100
IgAN HSP Non-IgAN
Fig. 1. Plasma levels of (A) actC3, (B) C4-C3
complexes and (C) sC5b-9 in patients with IgA
nephropathy, Henoch-Schonlein purpura and
non-immune renal disease. Shown are individual
measurements as well as box plots (median, box
showing 25th and 75th percentiles, lines
indicating 10th and 90th percentiles). Normal
ranges (means 2 SD) measured in healthy
persons are indicated by the hatched areas.
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Table 2. Spearman rank correlation coefficients between clinical findings and plasma concentrations of actC3, C4-C3 complexes, and sC5b-9 in
patients with IgAN (N = 50) or non-immune renal disease (N = 20)
Parameter Patients
ActC3
—
r P
C4-C3 complexes sC5b-9
r Pr P
Serum creatinine pmollliter IgAN
Controls
0.17
0.41
NS
NS
0.19
0.39
NS
NS
0.18
0.22
NS
NS
Creatinine clearance mI/mm IgAN
Controls
—0.06
—0.39
NS
NS
—0.20
—0.22
NS
NS
—0.15
—0.29
NS
NS
Proteinuria g/day IgAN
Controls
0.35
—0.33
<0.01
NS
0.27
—0.39
<0.05
NS
0.29
—0.29
<0.01
NS
Microhematuria million eiythroc.Iday IgAN
Controls
0.32
—0.29
<0.01
NS
0.17
—0.43
NS
NS
0.13
0.03
NS
NS
Time since renal biopsy months IgAN
Controls
—0.15
NA
NS
—
—0.04
NA
NS
—
—0.13
NA
NS
—
Age years IgAN
Controls
0.15
0.62
NS
<0.01
0.24
0.81
NS
<0.01
0.14
0.61
NS
<0.01
Abbreviations are: NA, not available, NS, not significant.
Plasma concentrations of actC3 were significantly increased in
patients with IgAN and HSP over those with non-immune renal
disease (Fig. 1). When the non-immune renal disease group was
used to define a control range (mean 2SD), plasma concentra-
tions of actC3 were elevated in one or two samples in 30% of the
patients with IgAN and 25% of the patients with HSP. In those
IgAN patients where two plasma samples were available, 67% had
normal actC3 concentrations on both occasions, 13% elevated
concentrations at both occasions and 18% showed elevated
concentrations at the first occasion only. Notably, only one IgAN
patient (2%) initially presented with a normal actC3 level and had
an increased level at the second occasion. In the HSP group both
samples with elevated actC3 concentrations were obtained from
the same patient within a period of three months.
In contrast to actC3, the plasma concentrations of C4-C3
complexes did not differ significantly between patients with IgAN,
HSP and non-immune renal disease (Fig. 1). When the non-
immune renal disease group was used again to define a control
range, plasma concentrations of C4-C3 complexes were increased
in four (8%) IgAN patients and in none of the HSP patients. In
three of the four patients, actC3 levels were increased at the same
time points as C4-C3 complexes were elevated.
Plasma concentrations of sC5b-9 were not significantly different
between patients with IgAN, HSP and non-immune renal disease
(Fig. 1), and none of the IgAN samples exceeded the control
range as defined by the non-immune renal disease group.
Correlation of complement activation with clinical status
As we predicted, neither actC3 plasma concentrations nor those
of C4-C3 complexes or sC5b-9 showed any correlation with serum
creatinines or creatinine clearances in patients with IgAN or
non-immune renal disease (Table 2). Similarly, no correlation
with a history of macrohematuria (data not shown) or the time
elapsed since renal biopsy evolved for any of the three comple-
ment components (Table 2). The degree of proteinuria was
weakly, yet statistically significantly correlated with levels of
actC3, C4-C3 complexes and C5b-9 in patients with IgAN, as were
actC3 levels and the degree of microhematuria (Table 2). Patient
age correlated significantly with all three complement compo-
nents in non-immune renal disease patients, but not in the IgAN
patients (Table 2).
Compared to IgAN patients with normal actC3 concentrations,
those with elevated levels had a shorter time since renal biopsy (an
occasionally used surrogate marker of renal disease activity),
exhibited higher proteinuria and more severe microhematuria
(Fig. 2). None of these differences reached statistical significance,
but all were within the 5 to 6% range of probability (Fig. 2). In the
case of C4-C3 complexes, IgAN patients with normal or elevated
levels differed significantly only in their extent of proteinuria
(Fig. 2).
Six of the 50 patients with IgAN and one of the HSP patients
were receiving corticosteroids at one or both occasions of obtain-
ing blood samples, so that 9 of 98 samples were obtained during
phases of immunosuppressive therapy. The plasma concentrations
of the three complement components were not significantly
different between the steroid-treated patients and those without
immunosuppressive therapy.
Predictive value of complement activation for the subsequent
course of the renal disease
Figure 3 and Table 3 show that a significant correlation existed
between the the level of actC3 at the first presentation and the
subsequent slope of 1/creatinine. In subgroup analyses this corre-
lation was found to be mainly due to the patients with normal
renal function at presentation (r =
—0.65; P = 0.006) while the
correlation in patients with already impaired renal function at
presentation failed to reach statistical significance (r =
—0.33;P =
0.13). If the analysis was confined to those patients followed for
more than one year (N = 34), the correlation between the slope
of 1/creatininc and actC3 levels persisted (r =
—0.502; P = 0.005).
Table 3 also demonstrates that actC3 levels and proteinuria at the
time of the first presentation showed similar correlations with the
slope of 1/creatinine, while that of the initial serum creatinine was
weaker and hematuria was not significantly correlated with the
slope of 1/creatinine.
When stable or improving renal function was arbitrarily defined
as a slope of 1/creatinine of greater than —5 X iO 1/(.tmol *
month) (Fig. 3), a single elevated actC3 level had a sensitivity of
75% and a specificity of 89% for predicting subsequent progres-
sion of the renal disease (Table 4). Specificity and sensitivity of a
single actC3 determination exceeded that of various other clinical
parameters used to predict progressive renal dysfunction (Table
4).
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Fig. 2. Comparison of clinical characteristics in
JgAN patients at the time of obtaining plasma
samples with normal (N = 71) or increased levels
of actC3 (N = 19), as well as with normal (N =
84) or increased levels of C4-C3 complexes (N =
6). Shown are box plots (median, box showing
25th and 75th percentiles, lines indicating 10th
and 90th percentiles). In the case of
microhematuria, excretion of >100 million
erythrocytes per day was set as 100.
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We also assessed whether evidence of complement activation in at all. As shown in Figure 4, IgAN patients with increased actC3
both blood samples carried a worse prognosis than increased levels on both occasions showed a faster rate of progression than
actC3 or C4.-C3 complex levels at only one occasion or no increase those with an increased level at only the first occasion or no
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Fig. 3. Correlation between plasma levels of
actC3 at the first presentation and the subsequent
slope of 1/creatinine in patients with IgAN.
Patients were arbitrarily divided into those with
decreasing renal function [slope below —5 X
ca iO l/(mol * month)1, stable renal function[slope between +5 and —5 >< iO l/(jsmol
month)] and improving renal function [slope
greater than +5 X iO l/(mol * month)].
Plasma actC3 levels were separated into those
greater than or within the control range, as
defined by the mean 2 SD of the non-immune
renal disease group. In all the patients
represented, the serum creatinine at the time of
0 the first presentation was below a maximum of
407 j.rmol/liter. Symbols are (•) Normal renal
—40 —30 20 —10 0 +10 +20 function at presentation; (U) Decreased renal
function at presentation. r =
—0.56; P = 0.003;
Slope of 1/creatinine liter/(p.mol*month)*1O_5 N = 44.
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Table 3. Spearman rank correlation coefficients between the slope of
1/creatinine and various parameters in patients with IgAN, in whom
more than 6 months of follow-op was available (N = 44)
Slope of 1/creatinine versus r = P=
actC3 levels af first presentation —0.56 0.003
serum creatinine at first presentation —0.32 0.04
proteinuria at first presentation —0.57 0.002
microhematuria at first presentation —0.17 NS
NS is not significant.
increases at all. In the case of increased C4-C3 complex levels, too
few patients showed elevated concentrations to allow a statistical
evaluation. However, it is noteworthy that all four patients with
elevated C4-C3 complex levels exhibited rapid progression rates
(Fig. 4).
Discussion
Our findings show that systemic evidence of complement
activation can be demonstrated in 30% of the patients with IgAN
and 25% with HSP. In 6% of the cases with IgAN, complement
activation apparently occurred via the classical pathway. However,
in the majority of our IgAN and HSP patients we could not detect
elevated C4-C3 complex levels, suggesting that in these patients
the elevated actC3 levels were the result of alternative pathway
activation. In contrast to actC3 and C4-C3 complexes, sC5b-9
plasma concentrations were within the control range in all IgAN
and HSP patients. This apparent discrepancy of early yet not late
activation of the complement pathway most likely relates to an
overall inefficiency of terminal sequence activation and has been
observed in other patients with complement-consuming immune
complex diseases as well [201.
Four previous studies have also assessed systemic complement
activation in patients with IgAN by measuring the complement
breakdown products [21—241. This approach is more sensitive than
the measurement of total complement C3 or C4 levels, none of
which are decreased in patients with IgAN or HSP [21, 25—271.
Lagrue et al [22] and Sølling [241 detected mild elevations of
complement C3d in 50% (5 of 10) and 45% (5 of 11) of their
patients, respectively. Wyatt et a! [21], using a radioimmunoassay
for a neoantigen expressed on fragments of C3, reported in-
creased plasma levels in 73% of 53 adult IgAN patients. These
authors also noted elevated C4d/C4 ratios, suggesting classical
pathway complement activation, in 28% of their IgAN patients
[21]. Finally, Brenchley et al [23], using an ELISA for C3dg,
detected increased plasma levels in 45% of 29 IgAN patients. In
that study, 17% of the patients also showed increased plasma
levels of sC5b-9 [23]. In comparing the results of these studies, it
is apparent that all former studies reported a higher prevalence of
systemic complement activation than we observed in the current
study. Several reasons may underlie this observation. First, instead
of using healthy persons as controls, we compared IgAN patients
with a non-immune renal disease group, which was comparable in
clinical characteristics. This excluded that non-specific effects on
the complement system, for example those related to hyperten-
sion, proteinuria or age, accounted for our findings. Indeed, actC3
and C4-C3 complex concentrations in several of the non-immune
renal disease patients were above the normal range, which is
similar to previous findings from our group [28]. On the other
hand, the samples from normal persons had not been stored for
Table 4. Sensitivity and specificity of various parameters to predict the
subsequent development of progressive renal insufficiency [defined as a
slope of 1/creatinine of less than —5 X iO l/(mol . month)] in patients
with IgAN, in whom more than 6 months of follow-up was available
(N = 44)
Parameter (at the time of the
first presentation) Specificity % Sensitivity %
actC3 level above control range 89 75
Proteinuria >1 g/24 hrs 44 93
Proteinuria >3.5 g/24 hrs 72 69
Elevated serum creatinine 58 69
Significant microhematuriaa 16 100
a Defined as >3 million erythrocytes/day
similar lengths of time and are therefore not strictly comparable
to the patient samples analyzed in the present study. Second, we
ascertained that none of the complement components measured
were influenced by renal dysfunction. In contrast, Sølling reported
that C3d plasma concentrations increased with renal dysfunction,
in particular in end-stage renal failure [24]. Similar findings have
also been observed for C3a and C4a in patients with IgAN [29].
Consequently, elevated plasma levels of C3d, C3a or C4a in
patients with IgAN as observed in these studies could be due to
some degree to renal retention. Finally, we ascertained that no
complement activation occurred ex vivo by adding a relatively high
EDTA concentration as well as benzamidine to the blood samples
and by rapidly freezing the plasma. These technical issues are of
importance, since it is well recognized that any coagulation will
activate the complement pathway [19, 30]. Conceivably, coagula-
tion triggered complement activation may be augmented by the
presence of immune complexes in the blood. This, for example,
could at least partially account for the observation of Kawana and
Nishiyama [31], who reported increased sC5b-9 levels in 83% of
their serum samples from patients with HSP.
In none of the previous studies described above [21—24] was
clinical follow-up available, and the concentrations of the various
complement components assessed were therefore only related to
the current or past clinical status. Wyatt et al [21] noted no
correlation between iC3b-C3d neoantigen concentrations and
several clinical parameters, such as proteinuria, presence of
chronic renal insufficiency and history of macrohematuria. In
contrast, the present study revealed weak, yet statistically signifi-
cant correlations between actC3 levels, proteinuria and microhe-
maturia. Furthermore, differences of the clinical status of patients
with and without elevated actC3 levels were also apparent when
those patient subgroups were compared to each other. In a similar
approach Brenchley et a! [23] described significantly more hema-
tuna in patients with increased C3dg plasma levels than in those
with normal levels. These data suggest that elevated levels of
actC3 or C3dg identify IgAN patients with high concurrent
disease activity. Although we can only describe an association with
no proof of causality, the data of the current study support the
hypothesis that complement activation, induced by IgA and/or
IgG immune complexes is a contributor to the pathogenesis of
renal disease in IgAN and, possibly, also in HSP.
The most important finding of the present study was that in
patients with IgAN plasma levels of actC3 showed a significant
correlation with the subsequent rate at which renal function was
lost. This correlation became even stronger when more than one
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plasma sample exhibited an elevated actC3 level. These findings
especially applied to patients with normal renal function at the
first presentation, suggesting that complement activation in IgAN
patients does not occur secondary to established renal impair-
ment. All of the aforementioned observations lend further sup-
port to the hypothesis that actC3 plasma levels reflect renal
disease activity and that complement activation contributes to the
pathogenesis of IgAN. More importantly, our data suggest that
assessment of actC3 could represent the first serologic test to
predict outcome in patients with IgAN. Compared to proteinuria,
which has frequently been used as a risk marker of progressive
IgAN [4, 6, 32, 33], the determination of actC3 had a somewhat
lower sensitivity but markedly improved specificity for predicting
subsequent deterioration of renal function. Conceivably, sensitiv-
ity and specificity of actC3 determinations might be enhanced
further if more than one plasma sample is analyzed.
In contrast to actC3, other serological tests, such as the
demonstration of circulating immune complexes, do not distin-
guish between patients with deteriorating and stable renal func-
tion [24]. The same has been reported for IgA fibronectin
complexes [34, 35]. Finally, urinary cytokine excretion, in partic-
ular interleukin-6, has been assessed in IgAN patients [36—38].
However, it is not clear whether the increased urinary interleu-
kin-6 excretion in some patients with IgAN reflects increased
proteinuria per se and whether it is indeed associated with a
progressive course of the disease.
We conclude that systemic complement activation, mainly via
the alternative pathway, can be detected in about one third of
patients with IgAN and in some patients with HSP. Several
findings support the notion that complement activation, in partic-
ular the detection of increased actC3 plasma levels, reflects high
degrees of renal disease activity. Given the association between
high actC3 levels and subsequent deterioration of renal function,
this complement component could potentially represent a novel
marker to non-invasively identify those patients who are most
likely to benefit from therapeutic intervention. At present, no
established therapy is available for patients with progressive types
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Fig. 4. Relationship between the slope of
licreatinine and the frequency of detecting
elevated levels of (A) actC3 and (B) C4-C3
complexes in those patients with IgA nephropathy
from whom two plasma samples were available.
Shown are individual measurements as well as
box plots (median, box showing 25th and 75th
percentiles, lines indicating 10th and 90th
percentiles).
of IgAN or HSP [1, 9]. However, if our observation is indepen-
dently confirmed in other populations of patients, elevated plasma
actC3 may become a useful entry criterion in future trials aimed
at the evaluation of novel therapeutic approaches to IgAN.
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